Covid 19 Research using Clinical Trials (Home Page)
HP:0002015: DysphagiaHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2399 | Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki | 1.00 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Oropharyngeal Dysphagia in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment of Patients Admitted by COVID-19 in the Consorci Sanitari Del Maresme
Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD in these patients and to know their needs of compensatory treatment. Methods: observational study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme. We will register also results of the EAT-10, nutritional status (MNA-sf/MUST/NRS), the needs of compensatory treatments of these patients (fluid and nutritional adaptation and use of nutritional supplements) and clinical complications during 6 months follow up.
NCT04346212 Oropharyngeal Dysphagia COVID-19 Sars-CoV2 Nutrition Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) MeSH:Deglutition Disorders
HPO:Dysphagia Oral-pharyngeal dysphagia
Primary Outcomes
Description: Prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Prevalence of oropharyngeal dysphagia Time: From April to July 2020.
Secondary Outcomes
Description: Eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Swallowing screening Time: From April to July 2020.
Description: Percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Swallowing status. Time: From April to July 2020.
Description: Nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Nutritonal status of study patient's. Time: From April to July 2020.
Description: Fluid (volume and viscosity) requirements of study patients.
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to July 2020.
Description: Nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to July 2020.
Description: Incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions). Time: 6 months from inclusion.
Description: Prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions). Time: 6 months from inclusion.
Description: Incidence: number of visits to the emergency department/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department). Time: 6 months from inclusion.
Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 6 months from inclusion.
Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Clinical complications at 6 months follow up from patient's medical history (respiratory complications). Time: 6 months from inclusion.
Description: 6 months mortality.
Measure: Clinical complications at 6 months follow up from patient's medical history (mortality). Time: 6 months from inclusion.
HPO Nodes
HP:0002015: Dysphagia
Genes 485
DNAJC13 LBR NEB FMR1 KCNAB2 GBA ATXN8OS SLC6A9 ADCY6 NEB SACS TBP SYT14 RRM2B TK2 PRPH GNAQ SLC52A3 TYMP CHMP1A MAPT CHD7 PDP1 SNCA ADD3 CLCN1 PCNA CCR6 CHRNA1 GFPT1 VAPB NCAPG2 NR4A2 MEGF10 SLC5A7 VPS13A TGM6 NUP62 ATP1A3 GIGYF2 COLQ HLA-B ATXN3 SCO2 NDUFS2 KMT2A SETBP1 CACNA1G SEMA3E POLG COL13A1 MYMK REEP1 GCH1 STUB1 MECP2 COL7A1 PABPN1 HLA-DQA1 IRF5 TRAPPC12 SDHD DNAJB6 FTL KIAA0319L HGSNAT COQ4 FLCN TPM2 EXOSC9 LRP12 SCARB2 SQSTM1 PLP1 WFS1 LAMA2 ATXN1 MYH8 MAPT DDHD2 SKI GBA VARS1 GEMIN4 AR NECTIN1 SELENON TAF1 KY PUS3 MYO9A MMP1 CNTNAP1 PLEC TBP DGUOK ATXN8OS COLQ FARS2 PFN1 QDPR TUBB4A TAF1 UBQLN2 ND5 CHCHD10 ZFYVE26 NPC1 HLA-DQB1 TBC1D23 C9ORF72 MAPT ALS2 TARDBP MYO9A SCN4A RARS1 PSAP SLC52A2 IRF5 AGRN ACTA1 SNAP25 MYORG MACF1 SLC9A6 CAV1 SNCAIP LRRK2 PRKCG ATP7B RNASEH1 ANKRD11 SPG7 MAP2K2 ATXN2 CHMP2B PYGM DDHD2 CHRNE HLA-DRB1 PLAA NOP56 NEK1 SPG7 ERLIN2 DMPK MSX1 SOD1 DKK1 STXBP1 CARS2 POLG MMP1 SLC25A1 ECM1 COL7A1 SLC19A3 TIMM8A TPM3 RERE DNAJB6 IRF2BPL RRM2B TRAPPC12 POLG PTS LMNB1 KCNK9 ATXN7 ACTA1 RYR1 ASPA FBXO7 PRKRA KIT MFF ATP6 SDHB TRNL1 NDUFS1 KCNC3 TANGO2 ND3 SLC18A3 SPG7 TK2 SNCA TRNW CAV1 CDH1 ND6 SLC52A3 FA2H HPCA NOTCH3 PIGN ASCC1 NDUFAF3 HPRT1 CAVIN1 TIMM8A NGLY1 FTL SPECC1L GDAP2 ALDH18A1 CTNS MAPT MGME1 TPM2 EIF4G1 DLX4 GRHL3 SYT2 LAMB2 DNM1L COL7A1 SLC25A4 SON POLR3A COL7A1 TUBB6 SDHC BRAF OPA1 DCTN1 IRF6 LIFR RRM2B GBA SDHB KIT TRIP4 KLHL7 NEFH CHRNA1 CHCHD10 VAMP1 SCN4A NUP62 ATXN10 NDUFB8 ATXN3 ADH1C SLC1A4 NGLY1 PDGFRA POLG SDHB POLR3A UBTF TOP3A REEP1 SCN4A ERLIN2 SURF1 ATXN8OS IDH2 MAPT FUS PRDM16 PLA2G6 NEUROD2 ATP1A3 MATR3 PANK2 NEB VAC14 GNS SDHC TPM3 SPG11 SLC9A6 GNAO1 RRM2B KLHL41 GALC CHRNE KCNK9 ATXN3 SDHC ND1 ADNP PIK3R5 XRCC1 HTT VAMP1 CHRND CHRND ACOX1 HLA-DRB1 PLEC LINGO1 RHBDF2 NPC2 RERE SQSTM1 YY1 NEB NRXN1 ACTA1 MYOT ADAR TAF1 COQ2 POLR3B KIF5A AFG3L2 ALS2 RNASEH1 MED17 ATP6 CYP27A1 FXN TWNK IKZF1 ATXN8 CYP7B1 POLR3A TTBK2 SPG21 PRKRA CARMIL2 POLG PMP22 ACTA1 DMPK POLG2 GBA2 DGUOK FLAD1 GRM1 VPS35 CHAT GJB1 CDC73 SERPING1 TP63 ATXN3 SYNJ1 REPS1 ATP7A MYOT REV3L UBTF PANK2 NONO CACNA1G GRIN2D MYH7 EPRS1 DLG1 PIGA QDPR ATP1A3 NDUFAF2 ARHGAP29 TANGO2 PANK2 CRYAB TWNK DYSF KIT MATR3 ATN1 SNCA CACNA1A CRLF1 PLXND1 B4GALNT1 YARS2 MAPT PANK2 GBA MID1 KLHL41 LMX1B VAMP1 SCN4A ATXN2 TARDBP POLR3B SLC25A22 TBK1 MECR KBTBD13 ATP13A2 TPM3 TK2 CDC73 TP63 IRX5 NDUFA6 PSEN1 PTS APP PNKD GRHL2 LMOD3 HOXB1 NECTIN1 CACNA1A PRPS1 NDUFS3 NF1 TBK1 KLHL40 MYPN SMC1A KAT6B ASAH1 ALS2 RLIM ACTB GBA PUF60 FRG1 MPZ SPART ITGB4 TUBB4A COL7A1 PRNP VAMP1 NOS1 ARX NOP56 ATXN8 C19ORF12 EBF3 SPG21 IDH1 NDUFA9 ND4 FBXL4 CNTNAP2 KLHL40 GUCY1A1 CCN2 CHAT OPTN UBB SLC5A7 TRNK BMP4 LMNB1 GABRD TBCD SETX FERMT1 MSX1 ND2 VCP AFG3L2 PEX16 POLG ATXN7 STUB1 ACTA1 GMPPA SDHA ACTG2 TRNV DAB1 PYROXD1 ATXN1 C12ORF65 CCR6 SIK1 RAI1 PDE8B TPM3 SCN3A PLA2G6 ALS2 KCND3 KLHL41 CCN2 ERLIN2 PLAA IRF6 SYT14 SETX GLUD2 Protein Mutations 1
V158M SNP 0
Primary Outcomes
Description: Prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Prevalence of oropharyngeal dysphagia Time: From April to July 2020.Secondary Outcomes
Description: Eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Swallowing screening Time: From April to July 2020.Description: Percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Swallowing status. Time: From April to July 2020.Description: Nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Nutritonal status of study patient's. Time: From April to July 2020.Description: Fluid (volume and viscosity) requirements of study patients.
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to July 2020.Description: Nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to July 2020.Description: Incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions). Time: 6 months from inclusion.Description: Prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions). Time: 6 months from inclusion.Description: Incidence: number of visits to the emergency department/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department). Time: 6 months from inclusion.Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 6 months from inclusion.Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Clinical complications at 6 months follow up from patient's medical history (respiratory complications). Time: 6 months from inclusion.Description: 6 months mortality.
Measure: Clinical complications at 6 months follow up from patient's medical history (mortality). Time: 6 months from inclusion.